DK2977053T3 - Sammensætninger og fremgangsmåder til behandling af cøliaki - Google Patents

Sammensætninger og fremgangsmåder til behandling af cøliaki Download PDF

Info

Publication number
DK2977053T3
DK2977053T3 DK15168279.6T DK15168279T DK2977053T3 DK 2977053 T3 DK2977053 T3 DK 2977053T3 DK 15168279 T DK15168279 T DK 15168279T DK 2977053 T3 DK2977053 T3 DK 2977053T3
Authority
DK
Denmark
Prior art keywords
gin
seq
peptide
pro
peptides
Prior art date
Application number
DK15168279.6T
Other languages
English (en)
Inventor
Robert Paul Anderson
Jessica Anne Stewart
James Anthony Dromey
Jason Allan Tye-Din
Original Assignee
Immusant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc filed Critical Immusant Inc
Application granted granted Critical
Publication of DK2977053T3 publication Critical patent/DK2977053T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)

Claims (16)

1. Sammensætning, der omfatter: i) et første peptid, der omfatter aminosyresekvensen PFPQPELPY (SEQ ID NO: 3) eller aminosyresekvensen PQPELPYPQ (SEQ ID NO: 4), ii) et andet peptid, der omfatter aminosyresekvensen PFPQPEQPF (SEQ ID NO: 10) eller aminosyresekvensen PQPEQPFPW (SEQ ID NO: 15) og iii) et tredje peptid, der omfatter aminosyresekvensen PIPEQPQPY (SEQ ID NO: 17) eller aminosyresekvensen EQPIPEQPQ (SEQ ID NO: 18) eller aminosyresekvensen QQPIPEQPQ (SEQ ID NO: 19).
2. Sammensætning ifølge krav 1, hvor (a) det andet peptid omfatter aminosyresekvensen PQQPFPQPEQPFPWQP (SEQ ID NO: 320), og/eller det tredje peptid omfatter aminosyresekvensen FPEQPIPEQPQPYPQQ (SEQ ID NO: 321); (b) det første, andet og/eller tredje peptid omfatter en N- terminal acetylgruppe eller pyroglutamatgruppe og/eller en C-terminal amidgruppe, fortrinsvis en N-terminal pyroglutamatgruppe og en C-terminal amidgruppe; (c) det første, andet og/eller tredje peptid er konjugeret til en forbindelse, hvor forbindelsen fortrinsvis er et adjuvans eller et MHC (major histocompatibility)-molekyle eller et bindingsfragment deraf; (d) to eller tre af det første, andet og tredje peptid er på en enkelt polypeptidkæde; og/eller; (e) sammensætningen omfatter et eller flere yderligere peptides, der omfatter en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209 og 210.
3. Sammensætning ifølge et hvilket som helst af kravene 1 til 2, hvor hver af det første, andet og tredje peptid uafhængigt er mellem 7 og 50 aminosyrer langt, eller hvor hver af det første, andet og tredje peptid er 20 eller færre aminosyrer langt.
4. Sammensætning ifølge krav 1, der omfatter: i) et første peptid, der består af aminosyresekvensen LQPFPQPELPYPQPQ (SEQ ID NO: 13) og en N-terminal og/eller C-terminal modifikation, fortrinsvis hvor det første peptid består af aminosyresekvensen pyroELQPFPQPELPYPQPQ-amid (SEQ ID NO: 228); ii) et andet peptid, der består af aminosyresekvensen QPFPQPEQPFPWQP (SEQ ID NO: 14) og en N-terminal og/eller C-terminal modifikation, fortrinsvis hvor det andet peptid består af aminosyresekvensen pyroEQPFPQPEQPFPWQP-amid (SEQ ID NO: 229); og iii) et tredje peptid, der består af aminosyresekvensen PEQPIPEQPQPYPQQ (SEQ ID NO: 16) og en N-terminal og/eller C-terminal modifikation, fortrinsvis hvor det tredje peptid består af aminosyresekvensen pyroEPEQPIPEQPQPYPQQ-amid (SEQ ID NO: 230) .
5. Sammensætning, der omfatter et eller flere polynukleotider, der koder for i) et første peptid, der omfatter aminosyresekvensen PFPQPELPY (SEQ ID NO: 3) eller aminosyresekvensen PQPELPYPQ (SEQ ID NO: 4), ii) et andet peptid, der omfatter aminosyresekvensen PFPQPEQPF (SEQ ID NO: 10) eller aminosyresekvensen PQPEQPFPW (SEQ ID NO: 15), og iii) et tredje peptid, der omfatter aminosyresekvensen PIPEQPQPY (SEQ ID NO: 17) eller aminosyresekvensen EQPIPEQPQ (SEQ ID NO: 18) eller aminosyresekvensen QQPIPEQPQ (SEQ ID NO: 19).
6. Sammensætning ifølge krav 5, der yderligere omfatter et eller flere polynukleotider, der koder for et eller flere yderligere peptider, der omfatter en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 47, 48, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 75, 76, 77, 78, 79, 80, 81, 89, 90, 91, 92, 95, 102, 103, 104, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 169, 170, 171, 172, 173, 174, 177, 178, 179, 180, 183, 184, 187, 188, 189, 190, 191, 192, 209 og 210.
7. Vaccine, der omfatter sammensætningen ifølge et hvilket som helst af kravene 1 til 6 og et farmaceutisk acceptabelt bæremateriale.
8. Vaccine ifølge krav 7, der yderligere omfatter et adj uvans.
9. Kit, der omfatter sammensætningen ifølge et hvilket som helst af kravene 1 til 5 og et middel til påvisning af binding af et eller flere peptider til T-celler.
10. Isoleret antigenpræsenterende celle, der omfatter peptiderne, polynukleotidet eller polynukleotiderne ifølge et hvilket som helst af kravene 1 til 6.
11. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, vaccine ifølge et hvilket som helst af kravene 7 til 8, kit ifølge krav 9 og/eller antigenpræsenterende celle ifølge krav 10 til anvendelse til diagnosticering eller terapi.
12. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, vaccine ifølge et hvilket som helst af kravene 7 til 8 og/eller antigenpræsenterende celle ifølge krav 10 til anvendelse til: (a) modulering af en T-cellerespons på et glutenpeptid hos en person, der er overfølsom over for gluten; (b) inducering af immuntolerans over for et glutenpeptid hos en person, der er overfølsom over for gluten; (c) behandling af cøliaki hos en person, der er overfølsom over for gluten; eller (d) modificering af cytokinsekretion hos en person, der er overfølsom over for gluten.
13. Fremgangsmåde til diagnosticering af cøliaki hos en person, overvågning af progression af cøliaki eller bestemmelse af effekten af en sammensætning, en vaccine og/eller en antigenpræsenterende celle til anvendelse ifølge krav 12, hvilken fremgangsmåde omfatter etablering af kontakt mellem en prøve fra personen og sammensætningen ifølge et hvilket som helst af kravene 1 til 6 og/eller vaccinen ifølge et hvilket som helst af kravene 7 til 8 og bestemmelse in vitro af, om et eller flere af peptiderne binder T-celler i prøven, hvor binding af et eller flere peptider til T-celler indikerer, at personen har eller er disponeret for cøliaki.
14. Fremgangsmåde til fremstilling af vaccinen ifølge krav 7 eller 8, hvilken fremgangsmåde omfatter kombinering af det første, andet og tredje peptid med et farmaceutisk acceptabelt bæremateriale.
15. Fremgangsmåde til bestemmelse af, om en anden sammensætning eller en fødevare er i stand til at forårsage cøliaki, hvilken fremgangsmåde omfatter påvisning af tilstedeværelse af sammensætningen ifølge et hvilket som helst af kravene 1 til 5 i den anden sammensætning eller fødevaren.
16. Sammensætning, vaccine og/eller antigenpræsenterende celle ifølge krav 12 til anvendelse ifølge krav 12, hvor sekretion af interleukin-2 (IL—2), interferon-gamma (IFNy) og/eller tumornekrosefaktor-alfa (TNFa) reduceres, og/eller sekretion af interleukin-10 (IL-10) forøges.
DK15168279.6T 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki DK2977053T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11864308P 2008-11-30 2008-11-30
EP20090828453 EP2367561B1 (en) 2008-11-30 2009-11-30 Compositions and methods for treatment of celiac disease

Publications (1)

Publication Number Publication Date
DK2977053T3 true DK2977053T3 (da) 2017-10-09

Family

ID=42225141

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09828453.2T DK2367561T3 (da) 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki
DK15168279.6T DK2977053T3 (da) 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09828453.2T DK2367561T3 (da) 2008-11-30 2009-11-30 Sammensætninger og fremgangsmåder til behandling af cøliaki

Country Status (16)

Country Link
US (5) US8835603B2 (da)
EP (3) EP2367561B1 (da)
JP (2) JP5851243B2 (da)
CN (2) CN105079781B (da)
AU (1) AU2009321481B2 (da)
BR (1) BRPI0922122A2 (da)
CA (2) CA3042826A1 (da)
DK (2) DK2367561T3 (da)
ES (2) ES2549481T3 (da)
HK (3) HK1162918A1 (da)
HR (1) HRP20150873T1 (da)
HU (1) HUE027237T2 (da)
MX (1) MX346450B (da)
NZ (1) NZ593474A (da)
PT (1) PT2367561E (da)
WO (1) WO2010060155A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2005237287B2 (en) 2004-04-28 2011-08-11 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP2367561B1 (en) 2008-11-30 2015-05-20 Immusant, Inc. Compositions and methods for treatment of celiac disease
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA3009238C (en) * 2011-01-20 2020-10-27 Cyrex Laboratories, Llc Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
ITRM20110487A1 (it) * 2011-09-19 2013-03-20 Consiglio Per La Ricerca E La Speri Mentazione In Peptidi aventi effetto protettivo nei confronti della attività infiammatoria del peptide 31-43 della a-gliadina nella malattia celiaca.
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
CA3191015A1 (en) 2012-02-07 2013-08-15 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
KR20220166879A (ko) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 펩티드 접합된 입자
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
US9913883B2 (en) 2013-03-13 2018-03-13 Cour Pharmaceuticals Development Company Immune-modifying nanoparticles for the treatment of inflammatory diseases
US20160041148A1 (en) * 2013-03-14 2016-02-11 Immusant,Inc. Placebo-controlled gluten challenge method
EP2994480A4 (en) * 2013-05-08 2017-05-17 JM Biologicals Compositions and methods for the production of gluten free food products
SI3033102T2 (sl) 2013-08-13 2024-03-29 Northwestern University Peptid konjugirani delci
CA2923822A1 (en) * 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
CA2925000A1 (en) * 2013-09-20 2015-03-26 Immusant, Inc. Compositions and methods related to oat sensitivity
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US20170045529A1 (en) * 2014-04-24 2017-02-16 Immusant, Inc. Methods of measuring antigen-specific t cells
WO2016040703A1 (en) * 2014-09-10 2016-03-17 Vibrant Holdings, Llc Peptide microarrays and novel biomarkers for celiac disease
AU2015323979A1 (en) * 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
CA2968422A1 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
KR101736744B1 (ko) 2014-12-03 2017-05-17 주식회사 한국유전자정보연구원 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20180250359A1 (en) * 2015-08-30 2018-09-06 Diamyd Medical Ab Combination therapy using gliadin and gamma aminobutyric acid
JP7194593B2 (ja) 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子
EP3416624B8 (en) 2016-02-18 2023-08-23 Cour Pharmaceuticals Development Company Inc. Process for the preparation of tolerizing immune-modulating particles
EP3464322B1 (en) * 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
WO2018005700A1 (en) 2016-06-28 2018-01-04 Immusant, Inc. Escalating dosage schedules for treating celiac disease
JP7089523B2 (ja) 2017-01-12 2022-06-22 プロビ アーベー プロバイオティクス組成物およびその使用
WO2018218250A2 (en) 2017-05-26 2018-11-29 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN111315768A (zh) 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
AU2018357840A1 (en) * 2017-10-30 2020-05-14 Immusant, Inc. Dosing regimens for celiac disease
JP6568193B2 (ja) 2017-12-19 2019-08-28 ホーユー株式会社 エピトープ
MX2020008301A (es) * 2018-02-08 2021-01-29 Cour Pharmaceuticals Dev Company Inc Tratamiento de la enfermedad celiaca con particulas tolerizantes.
EP3882261A4 (en) * 2018-10-31 2023-02-08 Ajinomoto Co., Inc. COMPOUND COMPRISING A SUBSTANCE HAVING AN AFFINITY FOR AN ANTIBODY, CLEAVAGE SITE AND CORRESPONDING REACTIVE GROUP OR SALT
WO2020181272A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP7374687B2 (ja) * 2019-09-26 2023-11-07 三和酒類株式会社 ペンタペプチド化合物
EP4061403A4 (en) * 2019-11-19 2023-12-27 Spark Therapeutics, Inc. SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
BR112023021222A2 (pt) 2021-04-16 2024-01-16 Cour Pharmaceuticals Dev Company Inc Método de rastreamento de manutenção de tolerância imunológica
WO2024020127A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740371A (en) 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
ATE77488T1 (de) 1986-03-06 1992-07-15 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JPH10511541A (ja) 1994-08-26 1998-11-10 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｔ細胞応答を調節するための方法および組成物
AU7726094A (en) 1994-09-02 1996-03-27 Immulogic Pharmaceutical Corporation Peptide compositions capable of down regulating an antigen specific immune response
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
EP1241476A1 (en) 2001-03-12 2002-09-18 Mabtech AB Diagnosis of metal allergy through cytokine release by T-cells in vitro
CA2440474A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
IL158342A0 (en) 2001-04-12 2004-05-12 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
AU2002347369A1 (en) 2001-12-05 2003-06-17 Circassia Limited Immunotherapeutic methods and systems
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
EP1507549A4 (en) 2002-05-14 2009-07-01 Univ Leland Stanford Junior MEDICAMENT THERAPY AGAINST CELIAC SPRUE
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
AU2003277989B2 (en) 2002-11-08 2010-04-22 QIAGEN Australia Holding Pty. Ltd. Diagnostic assay for measuring a cell mediated immune response
DK1563300T3 (da) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostisk fremgangsmåde til cøliaki
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
AU2005237287B2 (en) * 2004-04-28 2011-08-11 Btg International Limited Epitopes related to coeliac disease
GB0409775D0 (en) 2004-04-30 2004-06-09 Mabtech Ab Assay
WO2006050138A2 (en) 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
WO2007022477A2 (en) 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Methods and compositions to generate and control the effector profile of t cells
WO2007047303A2 (en) 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
DK3351268T3 (da) * 2007-01-25 2020-11-02 Intrexon Actobiotics Nv Behandling af immunsygdom ved mukosal indgivelse af antigener
ITFE20070003A1 (it) 2007-02-01 2007-05-03 Girolamo Calo' Utilizzo di peptidi ricchi in prolina e glutamina capaci di legarsi alle molecole hla-dq2 e dq8 come "carriers specifici" di agenti capaci di danneggiare o uccidere le cellule che esprimono dette molecole hla nel contesto dell a mucosa enterica di pa
AU2008229636B2 (en) 2007-03-16 2014-08-14 QIAGEN Australia Holding Pty. Ltd. A cell-mediated immune response assay and kits therefor
EP2659901B1 (en) 2008-04-21 2015-01-21 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
WO2009139887A2 (en) 2008-05-16 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Non-inflammatory gluten peptide analogues as biomarkers for celiac sprue
CA2731854C (en) 2008-07-25 2020-06-30 Cellestis Limited Measurement of cell-mediated immune response reactivity to detect or monitor a disease or condition
EP2367561B1 (en) 2008-11-30 2015-05-20 Immusant, Inc. Compositions and methods for treatment of celiac disease
US20120107847A1 (en) 2009-07-02 2012-05-03 Dsm Ip Assets B.V. Testing efficacy for celiac disease
US9459253B2 (en) 2009-12-23 2016-10-04 Cellestis Limited Assay for measuring cell-mediated immunoresponsiveness
WO2011146968A1 (en) 2010-05-28 2011-12-01 Cellestis Limited A diagnostic assay
US20110311536A1 (en) 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
SI2726883T2 (sl) 2011-06-29 2022-09-30 Cellestis Limited Test celično posredovanega imunskega odziva s povečano občutljivostjo
US20140248251A1 (en) 2011-07-25 2014-09-04 Daniel C. Adelman Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance
WO2013036293A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods
ES2402286B1 (es) 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
CN104254777B (zh) 2011-12-05 2016-08-24 伯乐实验室公司 重组脱酰胺化麦醇溶蛋白抗原
US20160041148A1 (en) 2013-03-14 2016-02-11 Immusant,Inc. Placebo-controlled gluten challenge method
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
CA2925000A1 (en) 2013-09-20 2015-03-26 Immusant, Inc. Compositions and methods related to oat sensitivity
US20170045529A1 (en) 2014-04-24 2017-02-16 Immusant, Inc. Methods of measuring antigen-specific t cells

Also Published As

Publication number Publication date
CA2744787C (en) 2019-06-11
JP5851243B2 (ja) 2016-02-03
CA2744787A1 (en) 2010-06-03
JP2016128402A (ja) 2016-07-14
EP2977053A1 (en) 2016-01-27
DK2367561T3 (da) 2015-08-24
AU2009321481B2 (en) 2014-08-21
HK1162918A1 (en) 2012-09-07
CA3042826A1 (en) 2010-06-03
JP6027215B2 (ja) 2016-11-16
HK1249446A1 (zh) 2018-11-02
US20210115096A1 (en) 2021-04-22
JP2012510431A (ja) 2012-05-10
BRPI0922122A2 (pt) 2017-08-01
CN105079781B (zh) 2018-07-20
US8835603B2 (en) 2014-09-16
MX346450B (es) 2017-03-17
HK1219898A1 (zh) 2017-04-21
US20150050303A1 (en) 2015-02-19
US9464120B2 (en) 2016-10-11
EP3269379A1 (en) 2018-01-17
PT2367561E (pt) 2015-10-23
NZ593474A (en) 2013-04-26
WO2010060155A1 (en) 2010-06-03
EP2367561B1 (en) 2015-05-20
HRP20150873T1 (hr) 2015-11-06
EP2367561A1 (en) 2011-09-28
ES2549481T3 (es) 2015-10-28
MX2011005632A (es) 2011-11-29
HUE027237T2 (en) 2016-10-28
US20170158743A1 (en) 2017-06-08
CN102438643A (zh) 2012-05-02
CN102438643B (zh) 2015-07-01
CN105079781A (zh) 2015-11-25
EP2367561A4 (en) 2012-06-06
AU2009321481A1 (en) 2011-07-07
ES2642096T3 (es) 2017-11-15
US20190048047A1 (en) 2019-02-14
US20110293644A1 (en) 2011-12-01
EP2977053B1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
DK2977053T3 (da) Sammensætninger og fremgangsmåder til behandling af cøliaki
EP3061766B1 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
AU2018274876A1 (en) Compositions and methods for treatment of celiac disease
US20160238590A1 (en) Compositions and methods related to oat sensitivity
US20200141924A1 (en) Peptides for use in treatment and diagnosis of type 1 diabetes
PL219272B1 (pl) Sekwencja DNA oraz sposób otrzymywania rekombinowanego alergenu pyłku traw Phl p4
Saarelainen Immune Response to Lipocalin Allergens-IgE and T-cell Cross-Reactivity (IgE-ja T-soluvälitteinen ristireaktiivisuus eläinperäisille lipokaliiniallergeeneille)